Neurocrine Biosciences (NBIX) Long-Term Deferred Tax (2020 - 2026)

At the end of FY2025, Neurocrine Biosciences' Long-Term Deferred Tax came in at $320.3 million, down 34.1% from FY2024.

• Annual Long-Term Deferred Tax shows a five-year compound annual growth rate of 0.1% (FY2020 to FY2025).
• In prior years, Neurocrine Biosciences' Long-Term Deferred Tax was $485.7 million in FY2024 (+33.9%), $362.6 million in FY2023 (+18.5%), $305.9 million in FY2022 (-2.9%) and $315.1 million in FY2021 (-1.3%).
• The Q2 2026 figure stands as the lowest quarterly Long-Term Deferred Tax in data going back to Q4 2020.
• On a year-over-year basis, Long-Term Deferred Tax has declined in each of the last four quarters, with an average decline of 7.8% over the last eight quarters.
• The strongest year-over-year quarter for Long-Term Deferred Tax in the past five years was Q4 2024, with growth of 33.9%; the weakest was Q2 2026, with a decline of 98.3%.
• According to Business Quant data, Long-Term Deferred Tax for the three prior quarters was $381.4 million (Q1 2026), $320.3 million (Q4 2025) and $368.5 million (Q3 2025).